Camargo Carlos A, Ramachandran Sulabha, Ryskina Kira L, Lewis Barbara Edelman, Legorreta Antonio P
EMNet Coordinating Center, Massachusetts General Hospital, Boston, MA 02114, USA.
Am J Health Syst Pharm. 2007 May 15;64(10):1054-61. doi: 10.2146/ajhp060256.
To evaluate the effectiveness of budesonide inhalation suspension relative to other common asthma therapies in a high-risk population, a study was conducted to compare the risk of having a repeat asthma-related hospitalization or emergency department (ED) visit in a Medicaid population of children; the relationship between asthma medication adherence level and repeat asthma hospitalizations or ED visits was also evaluated.
Children eight years of age or younger, with a hospitalization or ED visit for asthma between January 1999 and June 2001 (index event), were identified in a Florida Medicaid database. Claims data for each child were examined 12 months before and after the index event. Cox proportional hazards regression was used to model the risk of subsequent asthma exacerbation according to the asthma medication received during the first 30 days after the index event. Logistic regression was used to model the relationship between medication adherence as measured by the medication possession ratio (MPR) and the likelihood of a subsequent asthma exacerbation.
There were 10,976 children in the study. Patients who had a claim for budesonide inhalation suspension had a lower risk of a subsequent hospitalization or ED visit (hazard ratio, 0.55; 95% confidence interval, 0.41-0.76; p < 0.001) than patients who did not have budesonide inhalation suspension claims. Other controller medications were not associated with a reduction in the risk of subsequent asthma exacerbations. Adherence to medication was poor (a median MPR of 0.08 for budesonide inhalation suspension and a median MPR of 0.16 for any asthma controller medication). The odds of a repeat hospitalization or ED visit were significantly lower for children who were adherent to their asthma controller medication.
Children with asthma and insured by Medicaid were at a high risk of repeat exacerbations leading to increased hospitalizations and ED visits. Treatment with budesonide inhalation suspension in the first 30 days after a hospitalization or ED visit for asthma was associated with a significant reduction in the risk of repeat asthma-related hospitalizations or ED visits during the following year. Children who were adherent to their asthma controller medication had significantly lower odds of having a subsequent asthma exacerbation.
为评估布地奈德吸入混悬液相对于其他常见哮喘疗法在高危人群中的有效性,开展了一项研究,比较医疗补助计划覆盖的儿童群体中再次发生与哮喘相关的住院或急诊就诊的风险;还评估了哮喘药物依从性水平与再次哮喘住院或急诊就诊之间的关系。
在佛罗里达州医疗补助数据库中识别出1999年1月至2001年6月期间因哮喘住院或急诊就诊(索引事件)的8岁及以下儿童。在索引事件前后12个月检查每个儿童的理赔数据。采用Cox比例风险回归模型,根据索引事件后前30天接受的哮喘药物来模拟后续哮喘加重的风险。采用逻辑回归模型,以药物持有率(MPR)衡量的药物依从性与后续哮喘加重的可能性之间的关系。
该研究中有10976名儿童。有布地奈德吸入混悬液理赔记录的患者,其后续住院或急诊就诊的风险(风险比为0.55;95%置信区间为0.41 - 0.76;p < 0.001)低于没有布地奈德吸入混悬液理赔记录的患者。其他控制药物与后续哮喘加重风险的降低无关。药物依从性较差(布地奈德吸入混悬液的MPR中位数为0.08,任何哮喘控制药物的MPR中位数为0.16)。坚持使用哮喘控制药物的儿童再次住院或急诊就诊的几率显著更低。
参加医疗补助计划的哮喘儿童再次加重导致住院和急诊就诊增加的风险很高。在因哮喘住院或急诊就诊后的前30天内使用布地奈德吸入混悬液治疗,与次年再次发生与哮喘相关的住院或急诊就诊的风险显著降低相关。坚持使用哮喘控制药物的儿童后续哮喘加重的几率显著更低。